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The Intracellular and Extracellular Domains of BP180
Antigen Comprise Novel Epitopes Targeted by
Pemphigoid Gestationis Autoantibodies
Giovanni Di Zenzo1, Valentina Calabresi1, Fabiana Grosso1, Marzia Caproni2, Marina Ruffelli3 and
Giovanna Zambruno1
Pemphigoid gestationis (PG) is an autoimmune sub-epidermal bullous dermatosis of pregnancy associated with
circulating autoantibodies targeting the extracellular non-collagenous (NC) 16A domain of bullous pemphigoid
(BP) 180 antigen. In order to determine whether BP180 regions other than NC16A are recognized by PG
autoantibodies, we have analyzed the reactivity of 15 PG patient sera against several BP180 antigenic sites by
sensitive methods such as immunological screening and ELISA. Most PG sera tested (13 of 15) reacted with an
epitope (amino acid 508–541) mapped in the NC16A domain. Of note, nine of 15 PG patient sera reacted with at
least one additional antigenic site other than NC16A. Specifically, two epitopes in the BP180 extracellular
domain and five epitopes in the intracellular one were recognized by three and seven PG sera, respectively. In
addition, a representative intracellular epitope was recognized by PG autoantibodies as a portion of BP180
antigen both in denaturating and native conditions. Finally, reactivity against epitopes additional to NC16A was
also detected at an early stage of the disease. The identification and characterization of hitherto unrecognized
epitopes targeted by PG patient autoantibodies provide novel insights into the pathophysiology of humoral
immune response to BP180 in PG.
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INTRODUCTION
Pemphigoid gestationis (PG) is an autoimmune sub-epider-
mal bullous dermatosis associated with pregnancy. Clini-
cally, it is characterized by moderate-to-intense pruritus and
polymorphous skin eruptions. The lesions occur in most cases
during the last trimester and typically start at the abdomen
around the umbilicus and spread to other flexural areas of the
skin (Lin et al., 2001). Most patients heal after delivery, but
the disease usually recurs in following pregnancies (Jenkins
et al., 1999). PG shares similar clinical, histological, and
immunological features with bullous pemphigoid (BP), an
autoimmune disease of the skin and mucosae that typically
affects the elderly. Some cases of severe, long-term disease
may evolve into BP (Holmes et al., 1986). The immunological
hallmark of PG is the linear deposition of C3 along the
cutaneous basement membrane zone (BMZ), with IgG
detectable in only 25% of patients. As expected, the anti-
BMZ IgGs are predominantly of the complement fixing
subclasses IgG1 and IgG3 (Kelly et al., 1989; Chimanovitch
et al., 1999). The major target of PG patient autoantibodies is
BP180 (BP antigen 2 or type XVII collagen), an hemidesmo-
somal component (Morrison et al., 1988). This antigen is a
type II transmembrane glycoprotein which consists of a
globular cytoplasmic domain and a large extracellular region
containing 15 collagenous domains that form collagen-like
homotrimers in the extracellular milieu of the BMZ (Giudice
et al., 1992). PG sera may also recognize the BP230 antigen
(also called BP antigen 1), a cytoplasmic hemidesmosomal
protein implicated in the organization of the keratin filament
network (Kelly et al., 1990; Ghohestani et al., 1996). The
pathogenic relevance of anti-BP180 autoantibodies in PG is
supported by several experimental evidences: (1) the passive
transfer of rabbit IgG antibodies raised against murine
homolog immunodominant portion of BP180 into neonatal
mice induces a blistering disorder mimicking BP and PG
(Liu et al., 1993), and dermal–epidermal separation is also
observed in neonatal hamsters following passive transfer of
anti-BP180 antibodies (Yamamoto et al., 2002), (2) the
transplacentar transfer of anti-BP180 IgG from the mother
affected with PG into the neonate can cause a transient
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(3) the levels of anti-BP180 autoantibodies parallel disease
activity (Satoh et al., 1999; Sitaru et al., 2004), and (4) PG
autoantibodies induce dermal–epidermal separation in cryo-
sections of human skin (Herrero-Gonzalez et al., 2006). The
vast majority of BP and PG patients have circulating IgGs
reactive with the membrane-proximal non-collagenous (NC)
stretch of BP180 termed NC16A (Giudice et al., 1994;
Matsumura et al., 1996; Murakami et al., 1996). Interestingly,
some studies indicate that the anti-BP180 autoantibody
reactivity profile is different between PG and BP. BP patient
autoantibodies bind several epitopes, other than NC16A,
distributed over the entire BP180 molecule (Perriard et al.,
1999; Hofmann et al., 2002; Di Zenzo et al., 2004; Mariotti
et al., 2004), whereas the autoantibody reactivity in PG
patients appears to be mostly restricted to NC16A (Lin et al.,
1999; Perriard et al., 1999; Sitaru et al., 2003). Specifically,
preadsorption with glutathione S-transferase (GST) NC16A
recombinant protein abrogates binding of PG sera to the
extracellular domain (ECD) of BP180 (Lin et al., 1999; Sitaru
et al., 2003). However, the identification of a few PG sera,
reactive with BP180 by immunoblotting (IB) but NC16A-
negative by ELISA, has suggested the existence of additional
BP180 epitopes in PG (Sitaru et al., 2004).
In this study, to determine whether BP180 antigenic sites
other than NC16A are targeted by PG autoantibodies, we
have extensively characterized the reactivity of 15 PG sera
against a panel of BP180 epitopes using sensitive detection
methods. We have identified novel disease-specific BP180
epitopes and demonstrated for the first time a reactivity of PG
patient sera with intracellular epitopes of BP180, already
detectable at the moment of diagnosis.
RESULTS
The majority of PG patient sera react with BP180 antigen
The reactivity of PG patient autoantibodies against the BMZ
antigens was at first characterized by indirect immunofluor-
escence (IIF) and IB studies. IgGs of 11 PG sera bound to the
epidermal side of salt-split human skin, and 12 of 15 were
able to fix C3 at the same side (Table 1). In line with
previously reported data (Murakami et al., 1996), IB
analysis on cultured keratinocyte lysates showed that 53%
(8/15) of PG sera recognized BP180, whereas 13% (2/15)
reacted with BP230 (Table 1). Altogether, these techniques
detected circulating autoantibodies in 87% (13/15) of PG
patients.
PG sera significantly react against several epitopes distributed
over the entire BP180 molecule
Several studies have reported that PG sera reactivity is
restricted to the NC16A domain (Lin et al., 1999; Perriard
et al., 1999; Sitaru et al., 2003). To characterize the BP180
epitope pattern of patients affected by PG and to determine
whether their circulating IgGs were able to react against
BP180 epitopes located outside of the NC16A domain, we
assessed the reactivity of 15 PG sera against 15 BP180
Table 1. Clinical features of PG patients and sera reactivity in immunofluorescence and immunoblot analyses
IB4
Patient Age (years) NP Disease duration T1 IIF2 PGF3 BP180 BP230
PG1 31 I 1 w  1:5  + 
PG2 35 II (Y) 2 mo + 1:10 +  
PG3 31 I 2 w  1:10 + + +
PG4 33 II (N) 2 mo + 1:10 + + +
PG5 36 II (N) 1 w  1:20 +  
PG6 36 II (N) 2 yr  1:640 + + 
PG7 38 II (Y) 2 w     
PG8 21 I 1 mo  1:10 +  
PG9 35 I 1 yr + 1:10 + + 
PG10 28 II (N) 1 mo + 1:640 + + 
PG11 NK NK NK NK    
PG12 36 II (N) 1 mo   +  
PG13 26 I 4 mo +  + + 
PG14 27 I 1 w  1:20 + + 
PG15 41 III (Y) 1 w  1:40 +  
BP, bullous pemphigoid; IB, immunoblotting; IIF, indirect immunofluorescence; NK, not known; mo, month; NP, number of pregnancy (Y, PG in a previous
pregnancy; N, negative history for PG); PG, pemphigoid gestationis; PGF, pemphigoid gestationis factor; w: week; yr: year.
1BP sera taken before () and after (+) immunosuppressive therapy initiation.
2IgG titers by indirect immunofluorescence on salt-split human skin (labeling of the epidermal side).
3Pemphigoid gestationis factor assessed by complement-binding IIF assay on salt-split human skin (labeling of the epidermal side).
4Reactivity with BP180 and BP230 using cultured keratinocyte lysates.
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epitopes (Figure 1a). These epitopes had previously been
affinity selected from a BP180 random epitope l library using
sera from patients affected with BP (Di Zenzo et al., 2004).
The analysis was performed by immunological screening,
and ELISA using BP180 epitopes displayed on phage
transferred onto nitrocellulose filters and coated on ELISA
plates, respectively. Unexpectedly, PG sera reacted with
several epitopes distributed over the entire BP180 molecule.
Specifically, PG sera significantly bound three epitopes in the
intracellular domain (ICD) and three in the ECD by
immunological screening analyses (Table 2), and five
epitopes in the ICD and one epitope in the ECD by ELISA
(Table 3). Altogether, immunological screening and ELISA
results showed that eight BP180 epitopes were recognized
with a significantly higher frequency by PG patient sera than
by normal healthy individuals (Tables 2 and 3) and by 12
pemphigus serum samples (data not shown). Within the ICD
of BP180, the epitope (E-) 151 and E-176 were recognized by
five and four PG sera, respectively (Table 3). In addition, five,
three, and five PG sera bound to ICD epitopes E-292, E-299,
and E-353, respectively (Table 3). In line with previously
reported data (Giudice et al., 1994), most PG sera (13 of 15)
recognized the NC16A epitope E-508 in the BP180 ECD
(Table 2). Finally, the C-terminal epitopes E-1331 and E-1354
were recognized by three and two PG sera, respectively
(Table 2). Altogether, 60% of PG sera (9/15) recognized
additional BP180 epitopes and 47% (7/15) reacted with ICD
ones. Of note, the optical density (OD) values obtained by
ELISA with PG sera appeared similar for NC16A and
additional BP180 ICD and ECD epitopes (Table 3).
To determine whether PG patients (PG5 and PG7), who
did not react with the region encompassing residues 508–541
(E-508), were able to bind the entire NC16A domain, we
have also tested the reactivity of all PG sera with a phage
displaying the entire NC16A domain and with an ELISA
based on GST-NC16A fusion protein (Mariotti et al., 2004).
Using both methods only PG5 and PG7 sera did not react
with the entire NC16A domain (Table 3), confirming that
the amino acid (AA) stretch 508–541 comprises the major
NC16A epitopes recognized by PG sera (Giudice et al., 1994,
Herrero-Gonzalez et al., 2006). To further validate the
phage-ELISA employed in this study, we have tested PG sera
against previously generated GST fusions of the mid-portion
and C-terminal domain of BP180 (Mariotti et al., 2004),
confirming the results obtained with the ELISA based on the
same epitopes (E-1080 and E-1331) displayed on phage (data
not shown).
We have then evaluated the BP180 epitope profile in
relation to disease duration. Although findings were not
statistically significant owing to the small number of patients,
it is interesting to note that epitopes other than NC16A were
recognized not only by patients with a history of PG in
previous pregnancies (3/3, PG2, PG7, and PG15) and with a
disease duration of more than 2 months (2/3, PG9, and
PG13), but also by four (PG1, PG3, PG4, and PG10) out of
eight patients with a disease duration ranging from 1 week
to 2 months (Tables 1–3).
In conclusion, these findings indicate for the first time that,
in addition to NC16A, other epitopes both in the ICD and the
ECD of BP180 are significantly targeted by PG patient
autoantibodies.
Mapping of epitopes in the ICD of BP180 recognized by PG
autoantibodies
To further characterize reactivity of PG patient sera against
the ICD of BP180, we have assessed IgG subclasses of PG
circulating autoantibodies specific for an ICD epitope of
BP180 and evaluated the presence of independent epitopes
by competition assays. At first, to narrow the ICD antigenic
site E-292, the reactivity of E-292-positive sera (PG1, PG3,
PG7, PG9, and PG13) was tested against a previously
selected l phage displaying the region encompassing
residues 316–367 (E-316). All sera reacted with E-316
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Figure 1. The PG sera bind to the selected epitopes of BP180. (a) The
diagram represents the BP180 protein aligned with the 15 epitopes tested.
The AA residues that define the antigenic sites are indicated under the
epitope lines. PG-specific epitopes are shown as black lines, while epitopes
recognized with comparable frequency by both PG and control sera are
depicted as hatched lines. (b) The reactivity of 15 PG sera was assessed by
immunoscreening against the selected BP180 epitopes, as shown in some
representative filters. Positive signals are indicated (arrows) and correspond
to phages exposing BP180 peptides recognized by representative PG sera.
The PG2 filter shows the epitope positions in the matrix. (1) E-353; (2) E-508;
(3) E-567; (4) corresponds to the phage clone without any peptide exposed
on its capsid surface; (5) E-1331; (6) E-282; (7) corresponds to the phage
clone with unrelated peptide 1; (8) E-1080; (9) E-915; (10) E-292; (11) E-176;
(12) E-773; (13) E-299; (14) E-120; (15), E-151; (16) E-1354; (17), E-266;
(18) corresponds to the phage clone with unrelated peptide 2. The control
serum (normal healthy individual 1) does not show any positive signal.
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that the E-316 epitope, but not a control phage, is able to
inhibit the binding of PG sera autoantibodies to E-292 (data
not shown). We have then assayed by ELISA the IgG subclass
reactivity of five PG sera (PG1, PG3, PG7, PG9, and PG13)
against a recombinant fusion protein that corresponds to
E-316 (GST-316). IgG1 and IgG3 reactivity could be detected
in one and two PG sera, respectively (data not shown). To map
the epitopes comprised in the region AA 299–399, we then
assayed the reactivity of the five PG sera against the three
overlapping epitopes E-292, E-299, and E-353 by a compe-
titive inhibition ELISA with a recombinant fusion protein that
corresponds to E-316 (GST-316). All five sera had been
shown to react to the regions AA 292–367 and AA 353–399,
and three of them (PG1, PG9, and PG13) also recognized the
stretch AA 299–354 (Table 3). The GST-316 fusion protein
inhibited the reactivity of PG1, PG9, and PG13 against the
regions AA 299–354 and AA 292–367, but not against the
region encompassing residues 353–399 (Figure 2a). These
findings indicate the presence of at least two antigenic sites: a
first one spanning 316–354, shared by stretches AA 299–354
and AA 292–367, a second one encompassing residues
367–399 in the region AA 353–399 (Figure 2b). The reactivity
of PG3 and PG7 to the stretches AA 292–367 and AA
353–399 was completely abolished by competition with GST-
316 fusion protein (Figure 2c). These results indicate that PG3
and PG7 sera bind to a distinct antigenic site encompassing
residues 353–367, that is comprised in the overlapping
fragments AA 292–367, AA 353–399, and GST-316 (Figure
2d). Altogether, these findings demonstrate the presence of
at least three independent disease-specific epitopes in the
region AA 299–399.
Polyclonal antibodies raised against GST-316 react with BP180
To assess whether the reactivity against epitopes located
outside NC16A domain could be abolished by denaturing
conditions, the representative ICD epitope GST-316 was
assayed by IB using two sera, PG3 and PG7, the latter being
negative for BP180 by IB on keratinocyte extracts (Table 1).
Both PG sera reacted with the fusion protein GST-316 (data
not shown). To further characterize the reactivity against
this intracellular portion of BP180, we have produced a
polyclonal antibody by immunizing rabbit with GST-316
recombinant protein. The anti-GST-316 antibody was able to
stain the epidermal side of salt-split-skin by IIF (Figure 3a) and
to detect BP180 by IB (Figure 3b).
PG autoantibodies anti-GST-316 react with the BP180 molecule
To establish whether the intracellular epitopes were recog-
nized only as BP180 fragments or also within the context of
the entire BP180 molecule, we have affinity purified PG3
Table 2. Reactivity by immunological screening of 15 PG sera against 15 BP180 epitopes
ICD ECD


















2/152 2/15 3/153 0/15 0/15 4/153 2/15 4/153 13/153 1/15 0/15 2/15 0/15 3/153 2/153
NHI sera 2/642 1/64 0/64 1/52 4/52 4/64 1/64 1/52 0/64 2/64 0/64 1/64 0/64 0/64 0/64
E, epitope; ECD, extracellular domain; ICD, intracellular domain; NHI, normal healthy individual; PG, pemphigoid gestationis.
Reactivity by immunological screening with PG sera diluted 1:400 on BP180 epitopes blotted onto nitrocellulose filters. Tint represent positive signals, non
tint negative ones. The results were confirmed by three independent experiments.
1E-120 represents the first AA residue of the epitope sequence (see Figure 1a).
2Number of sera reactive/total number of sera tested.
3Statistically significant difference in reactivity between patients with PG and NHI sera (Pp 0.05 by Fisher’s exact probability test).
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autoantibodies against a representative antigenic site in the
BP180 ICD by using a GST-316 column. The immunopurified
serum was specific for E-316 and did not react with other
BP180 epitopes (data not shown). A 10-fold concentrated
preparation of these specific autoantibodies was able to stain
the epidermal side of salt-split-skin by IIF (Figure 3c) and to
detect the BP180 molecule by IB on keratinocyte extracts
(Figure 3d). These findings indicate that patient autoantibo-
dies specific for the ICD of BP180 recognize the epitope
within the context of BP180 molecule in both denaturating
and native conditions.
DISCUSSION
To gain better insight into the pathophysiological mechan-
isms of anti-BP180 reactivity in PG patients, we have
characterized the reactivity profile of 15 PG patient sera
against 15 BP180 epitopes by using sensitive detection
methods such as immunological screening and phage-ELISA.
Our findings provide evidence of a hitherto unrecognized PG
sera reactivity with several BP180 epitopes, in addition to
NC16A. Specifically, we have been able (1) to identify novel
epitopes in the ICD and ECD of BP180 targeted by PG sera;
(2) to map three independent epitopes within ICD of BP180;
(3) to demonstrate a specific reactivity against a representa-
tive BP180 intracellular epitope (E-316) that is recognized
within the context of the antigen in both denaturating
and native conditions. Importantly, our findings also show
that reactivity against intracellular epitopes, in addition to
that against NC16A, can be observed immediately after
disease onset.
Using a panel of BP180 epitopes displayed on l
bacteriophage, we have shown that PG patient autoanti-
bodies also bind epitopes on the BP180 antigen outside of
NC16A domain. Noteworthy, these newly identified PG
epitopes (E-151, E-176, E-292, E-299, E-353, E-1331, and
E-1354) were located not only in the ECD but also in the ICD
of BP180 antigen. In particular, 60% of PG sera (9/15)
recognized additional BP180 epitopes and 47% (7/15)
reacted with ICD ones. The differences in the reactivity
patterns obtained by ELISA and immunological screening
could be owing to the different sensitivity of these detection
methods and also to conformational changes induced into the
antigenic sites by the different coating support. Previous
studies could not detect any reactivity of PG sera against
antigenic sites additional to NC16A domain (Lin et al., 1999;
Perriard et al., 1999). These negative findings could be
Table 3. Reactivity by ELISA of 15 PG sera against 16 BP180 epitopes
ICD ECD
PG sera E-1201 E-151 E-176 E-266 E-282 E-292 E-299 E-353 E-508 NC16A E-567 E-773 E-915 E-1080 E-1331 E-1354
PG1 — 1.492 0.397 0.569 — 0.756 0.674 0.500 0.301 0.602 — — — — — —
PG2 — — 0.885 — — — — — 2.072 1.763 — — — — — 0.358
PG3 — 0.771 — — — 2.262 — 2.321 0.684 2.705 — — — — — —
PG4 — 0.669 — — — — — — 0.571 0.961 — — — — — —
PG5 — — — — — — — — — — — — — — — —
PG6 — — — — — — — — — 0.464 — — — — — —
PG7 — — — — — 1.787 — 0.574 — — — — — — — —
PG8 — — — — — — — — 0.314 0.699 — — — — — —
PG9 0.405 2.806 2.218 — — 0.586 0.671 0.781 0.715 1.022 — — — — — —
PG10 — — — — — — — — 0.331 0.497 — — 2.380 0.557 1.606 1.551
PG11 — — — — — — — — 0.391 0.721 — — — — — —
PG12 — — — — — — — — 0.404 0.946 — — — — — —
PG13 0.601 0.974 0.745 — — 0.546 0.334 0.875 2.063 2.113 — — — — — —
PG14 — — — — — — — — 1.331 1.730 — — — — — —
PG15 — — — — — — — — 0.781 0.842 — — — — 2.486 —
Cutoffs 0.262 0.330 0.285 0.370 0.290 0.200 0.280 0.270 0.180 0.160 0.299 0.315 0.321 0.253 0.315 0.200
Positive
PG sera
2/152 5/153 4/153 1/15 0/15 5/153 3/153 5/153 12/153 13/153 0/15 0/15 1/15 1/15 2/15 2/15
NHI sera 1/302 1/30 1/30 0/30 0/30 3/34 0/30 1/30 0/30 0/30 0/30 0/30 0/30 0/30 0/30 0/30
BP, bullous pemphigoid; E, epitope; ECD, extracellular domain; ELISA, enzyme-linked immunosorbent assay; ICD, intracellular domain; NC, non-
collagenous; NHI, normal healthy individual; PG, pemphigoid gestationis.
All the values are expressed as the mean OD reading obtained with parental phage l subtracted from the mean reading obtained with phage displaying
BP180 epitopes. Only values corresponding to positive signals are shown. All — correspond to negative signals below the cutoff value.
1E-120 represents the first AA residue of the epitope sequence (see Figure 1a).
2Number of sera reactive/total number of sera tested.
3Statistically significant difference in reactivity between patients with PG and NHI sera (Pp0.05 by Fisher’s exact probability test).
868 Journal of Investigative Dermatology (2007), Volume 127
G Di Zenzo et al.
PG IgGs Target ICD and ECD of BP180 Antigen
ascribed to the limited sensitivity of detection methods
employed combined with low titer of circulating autoanti-
bodies or, less likely, to immunological differences between
different subsets of PG patients tested. Indeed, several of our
PG patient sera, which proved BP180 negative by IB on
keratinocyte extracts, reacted with BP180 epitopes by ELISA
suggesting that the sensitivity of the techniques used could be
the limiting factor in the detection of PG sera reactivity
against additional BP180 epitopes. Furthermore, PG sera
reactivity against E-316 was not abolished by denaturating
conditions, as shown by IB results using GST-316. Finally,
both a rabbit polyclonal antibody raised against GST-316 and
immunopurified concentrated patient autoantibodies specific
for this ICD epitope were able to detect BP180 by IB and to
stain the epidermal side of salt-split human skin by IIF.
Altogether, these findings show a specific reactivity of PG
sera against BP180 epitopes additional to NC16A, which is
detectable by using sensitive assays such as ELISA and
immunological screening.
Our findings confirm once more that the vast majority of
PG patient sera react with NC16A, which is also the immuno-
dominant epitope recognized by most BP sera (Giudice et al.,
1994; Matsumura et al., 1996; Murakami et al., 1996). When
comparing data obtained using the same techniques on BP180
epitope profile of BP and PG sera, PG patients appear to
recognize ECD epitopes different from NC16A (3/15, 20%)
less frequently than BP sera (32/78, 41%) (Mariotti et al.,
2004), and to bind ICD epitopes (5/15, 33%) with a compar-
able frequency to that reported for BP patients (17/57, 30%)
(Di Zenzo et al., 2004). However, two ICD epitopes (E-176
and E-292) seemed to be recognized more frequently by PG
(3/15, 20% and 4/15, 27%, respectively) than BP patients
(6/57, 11% and 5/57, 9%, respectively) (Di Zenzo et al.,
2004). Further studies on a larger cohort of PG patients are
required to confirm these preliminary data on epitope profile





















































Figure 2. Five PG sera recognize three independent epitopes in the BP180
region encompassing residues 292–399. (a) Competitive inhibition ELISA
with PG1, PG9, and PG13 sera against the epitopes E-292, E-299, and
E-353. Reactivity of PG sera is almost completely abolished by competition
with GST-316 epitope, whereas reactivity against E-353 is not affected.
(b) Schematic representation of the overlapping fragments coated an ELISA
plate (black lines) and the competitive fusion protein GST-316 (gray line).
The assay shows the existence of two independent epitopes (hatched lines)
encompassing residues 316–354 and 367–399. (c) Competitive inhibition
ELISA with PG3 and PG7 sera against the epitopes E-292 and E-353.
Reactivity of PG sera is completely abolished by competition with
GST-316 epitope. (d) Schematic representation of the overlapping fragments
coated an ELISA plate (black lines) and the competitive fusion protein
GST-316 (gray line). The assay shows the existence an epitope (hatched line)
encompassing residues 353–367 localized in the overlapping region









Figure 3. Human and rabbit anti-GST-316 antibodies react with the
epidermal side of salt-split human skin and with BP180 antigen. (a) A rabbit
polyclonal antibody raised against the fusion protein GST-316 (encompassing
residues 316–367) stains the epidermal side of salt-split human skin by IIF
and (b) reacts with BP180 antigen by IB on keratinocyte extracts (lane 1,
anti-GST-316 polyclonal antibody; lane 2, preimmune rabbit serum).
Dilution of polyclonal and preimmune rabbit sera was 1:10,000. (c) In a
similar way, immunopurified and concentrated PG3 serum stains the
epidermal side of salt-split human skin by IIF and displays reactivity by
IB on keratinocyte extracts (d, lane 2 PG serum, lane 3 PG serum affinity
purified against the epitope GST-316). 1A8c is a mAb against BP180 used
as positive control (lane 1).
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According to the current model of autoimmune disease, it
has been postulated that the autoimmune response in BP is
initiated against the BP180 ECD and followed by a reactivity
that involves different autoantigens and/or epitopes both in
the ICD and ECD of BP180 antigen (Chan et al., 1998). A
similar epitope-spreading phenomenon, in which the appear-
ance of autoantibodies to the ECD of BP180 precedes the
development of autoreactivity against the ICD epitopes,
could occur also in PG. In line with this model, in this study,
we have shown for the first time a frequent reactivity with
BP180 epitopes additional to NC16A in PG patients (5/6)
with a history of PG in previous pregnancies or with a disease
duration of more than 2 months. Interestingly, also several PG
patients (4/8) with a shorter disease duration recognized ECD
and ICD epitopes in addition to NC16A showing that
reactivity against multiple epitopes, including ICD ones,
can be detected at an early stage of the disease. These
findings parallel a recent report showing that in BP patients, a
reactivity against BP180 ICD can occur near the time of
disease onset (Di Zenzo et al., 2004). The role of complement
in the pathogenesis of sub-epidermal autoimmune bullous
diseases in humans is not yet fully established. However,
complement activation mediated by anti-BMZ autoantibodies
has been reported in both PG and BP (Katz et al., 1976;
Gammon et al., 1982; Liu et al., 1995; Yamamoto et al.,
2002). In this context, the possible role of the IgG1 or IgG3
reactivity against a representative intracellular BP180 epi-
tope, detected in three out of five PG patients, awaits further
investigation.
Several experimental data suggest an involvement of
intracellular antigens in the development of blistering lesions
in sub-epithelial autoimmune bullous disorders. In particular,
it has been reported that (1) mucous membrane pemphigoid
sera targeting an intracellular domain of b4 integrin were able
to cause dermal–epidermal separation in an organ culture
model based on oral mucosa (Bhol et al., 2003), and (2) the
passive transfer in neonatal mice of antibodies against BP230
peptides was able to induce sub-epidermal blister formation
(Kiss et al., 2005). As to PG, there are evidences of cell
degeneration events that can cause the exposure of intra-
cellular epitopes. First, a focal liquefaction degeneration or
necrosis of basal keratinocytes is observed much more
frequently in PG than in BP (Hertz et al., 1976; Shornick
et al., 1983; Ban et al., 1998). Second, the massive presence
of cytotoxic anti-human leukocyte antigen class I and class II
antibodies that are at least temporally related to the
development of PG might cause a high frequency of
immunologic insult during gestation (Shornick et al., 1993).
In fact, the incidence of anti-human leukocyte antigen
antibodies increases in ‘‘complicated’’ pregnancies suggest-
ing that they may reflect a placental damage (Rocklin et al.,
1979). On the other hand, it has been demonstrated that the
circulating PG autoantibodies that react with skin BMZ
antigens also bind to the amniotic epithelial BMZ (Ortonne
et al., 1987). It is tempting to speculate that tissue injury and
cell damage in placenta could induce an early exposure of
intracellular antigens with subsequent production of specific
autoantibodies recognizing both amnion antigens and
different BP180 ICD and ECD epitopes early in disease
course. In this context, different epitopes might contribute to
amplify the immune response that is mainly dependent on the
recognition of the NC16A domain, as recently shown by an
in vitro model (Herrero-Gonzalez et al., 2006).
In conclusion, our study provides novel insights into the
humoral immune response to BP180 in PG patients. In
particular, we have reported a hitherto unrecognized
reactivity against both ICD and ECD of BP180, in addition
to NC16A. Based on our data and previous observations
(Sitaru et al., 2004), it is tempting to hypothesize that this
reactivity could contribute, together with that against NC16A
domain, to the pathogenesis of PG. However, further studies
are needed to assess the possible role of these additional
antigenic sites in the initiation and/or development of the
disease. Finally, the identification and mapping of BP180
epitopes recognized by PG autoantibodies could provide a
useful support for diagnosis of PG and be relevant for the
design of innovative therapies, for example, based on immuno-
modulatory approaches or on specific immunoadsorption
strategies in patients with severe disease.
MATERIALS AND METHODS
Patients and controls
In this study, we retrospectively investigated the sera from 15
patients with PG and 76 controls. The clinical diagnosis of PG was
confirmed by direct immunofluorescence assay, showing a linear
deposition of IgG and/or C3 along the BMZ, and by IIF assay,
showing IgG autoantibodies binding the epidermal side of 1 M NaCl
split human skin (Table 1). Nine PG patients had not begun any
specific treatment and five were treated at the time of blood draw (no
information about treatment status of the remaining patient was
available) (Table 1). Fourteen PG patients presented only skin blisters
without any mucous membrane involvement, no information about
the remaining patient (PG11) was available. Three of 14 patients
reported PG lesions in a previous pregnancy (Table 1). Controls
included 12 pemphigus patient sera positive by direct immuno-
fluorescence and IIF (autoantibodies reacting with the surface of
epithelial cells of monkey esophagus) and sera from 64 normal
healthy individual. The study was conducted in accordance with the
Declaration of Helsinki Principles and approved by the IDI-IRCCS
Ethic Committee; all patients gave informed consent.
IIF assays
IIF and complement-binding IIF were performed using 1 M NaCl-split
normal human skin as substrate, according to standard procedures
(Hodge et al., 1978).
IB procedure
IB was performed with epidermal proteins extracted from normal
human keratinocyte cultures or GST fusion proteins. The keratino-
cyte extracts and fusion proteins were fractionated under reducing
conditions by 6 and 10% SDS-PAGE, respectively, and blotted onto
polyvinylidene fluoride membrane Immobilon-P (Millipore, Bedford,
MA). As to GST fusion protein, a molar equivalent amount of GST
was run as control. Filters were incubated with blocking solution
(5% milk, 0.1% Tween 20 in 1 Tris-buffered saline) for 2 hours at
room temperature (RT). Serum samples were diluted 1:100 and
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incubated with blocking solution on filters overnight at 41C. In case
of fusion proteins, sera were preincubated for 2 hours at RT with
60 mg/ml of GST and 25 ml/ml of bacterial extracts. After washing
(0.1% Tween 20 in 1 Tris-buffered saline), the filters were
incubated with an alkaline phosphatase-conjugated rabbit anti-
human IgG (Hþ L) (Southern Biotechnology Associates Inc.,
Birmingham, AL) for 1 hour at RT, washed, and stained with
330mg/ml of nitro blue tetrazolium and 165 mg/ml of 5-bromo-4-
chloro-3-indolyl phosphate (Roche Diagnostics, Basel, Switzerland).
Immunological screening
The immunological screening procedure was performed as de-
scribed previously (Di Zenzo et al., 2004). Briefly, recombinant
phages displaying BP180 epitopes were grown as plaques and
blotted onto a nitrocellulose filter (Millipore). The filters were
blocked for 3 hours at RT. Ten microliters of each PG serum was
preincubated for 30 minutes at 371C with bacterial extracts and l
control phage. This mixture was added to the nitrocellulose filter and
incubated overnight at 41C. Then, the filters were washed and incu-
bated with an alkaline phosphatase-conjugated goat anti-human IgG
(Fc-specific) (Sigma, St Louis, MO) for 1 hour at RT and stained with
chromogenic substrates. To confirm the results, three independent
experiments were performed.
ELISAs based on phages displaying BP180 epitopes
Immunomicrotiter plates (Nunc, Roskilde, Denmark) were coated
with rabbit anti-l polyclonal antibodies, in 100 ml of 50 mM
bicarbonate buffer (pH 9.6), overnight at 41C. Wells were washed
four times and blocked for 1 hour at 371C. Each phage clone
displaying a specific BP180 epitope was prepared as a lysate
(Sambrook et al., 1989). Plaque-forming units (2 109) of recombi-
nant phages displaying BP180 epitopes were added to each well and
incubated for 1 hour at 371C. Serum samples were diluted 1:100 in
100ml of blocking solution and incubated, with the preincubation
mixture (1ml bacterial extracts, 1 ml rabbit serum, 1 ml fetal bovine
serum, and 109 plaque-forming units of parental l phage) for
30 minutes at RT. The mixture was then added to each well and the
plates were incubated for 1 hour at 371C. After washing, horseradish
peroxidase-conjugated rabbit anti-human IgG (Southern Biotechno-
logy Associates Inc.), diluted 1:20,000 in 100ml of blocking solution
with rabbit serum (1:40) was added for 1 hour at 371C. Wells were
washed and developed with 3,30,50,5-tetramethylbenzidine (Sigma).
After 20 minutes, the reaction was stopped, and OD at 450 nm, with
the correlation wavelength set at 655 nm, was measured using a
microplate reader (Bio-Rad Laboratories Inc., Hercules, CA). Each
serum was assayed in duplicate for the reactivity with each
recombinant phage and the mean OD reading obtained with
parental l phage was subtracted from the mean reading obtained
with recombinant phages displaying BP180 epitopes.
Fusion protein production and construction of phage displaying
NC16A domain
Two GST fusion proteins were expressed in E. coli DH5a by cloning
in pGEX-3X vector (Amersham Biosciences, Piscataway, NJ), the
previously generated cDNA fragment AA 490–562 (NC16A) (Mariotti
et al., 2004), and a cDNA fragment encoding the AA stretch
316–367. The latter was generated amplifying by PCR the genome
of l clone displaying the previously selected epitope E-316
(unpublished data) with primer pairs as follows: 50-ACGTTCCGT
TATGAGGATGT-30 and 50-CCACTACGTGAACCATCAC-30. The
amplified fragment comprised the epitope coding sequence between
SpeI and NotI restriction sites according to the sequence of parental
vector l171loxP (Santi et al., 2000). To generate a vector allowing
direct cloning, the vector pGEX-3X (Amersham Biosciences) was
modified by adding an adapter comprising SpeI and NotI restriction
sites in its polylinker. The adapter sequence was:
50-GATCCTGACTAGTTTTAAAGCGGCCGCG-30
30-GACTGATCAAAATTTCGCCGGCGCTTAA-50
Thus, the amplified fragment was digested with SpeI and NotI
restriction enzymes and cloned in frame with GST protein in this
modified vector. The two fusion proteins, termed GST-NC16A
and GST-316, were purified by affinity chromatography using
Glutathione-Sepharose 4B (Amersham Biosciences). To generate a
phage displaying the NC16A domain, the corresponding cDNA
was amplified by PCR using the BP180 cDNA as template with
primers pair: 50-GGACTAGTGAGGAGGTGAGGAAGCTG-30 and
50-ATTGCGGCCGCCATTTTCCTGTTCCATCAT-30. The underlined
sequences represent the SpeI and NotI restriction sites. After SpeI and
NotI digestion, the fragment was cloned into the genome of vector
l171loxP (Santi et al., 2000).
ELISAs based on recombinant proteins
Anti-GST-NC16A reactivity was detected by an ELISA assay based
on NC16A recombinant protein (Mariotti et al., 2004) and anti-GST-
316 reactivity was detected with an identical ELISA procedure.
Briefly, immunomicrotiter plates (Nunc) were coated with GST
recombinant protein (400 ng of GST-NC16A, 390 ng of GST-316)
and a molar equivalent of GST in 50 ml of coating buffer for 2 hours at
RT. Wells were washed and blocked overnight at 41C. Serum
samples diluted 1:100 and supplemented with bacterial extracts
were added to each well and incubated for 2 hours at RT. After
washing, horseradish peroxidase-conjugated rabbit anti-human
IgG (Southern Biotechnology Associates Inc.), diluted 1:20,000,
was added for 1 hour at RT. For IgG subclass analysis, serum
samples were incubated with mouse monoclonal anti-human IgG1
(clone: 8c/6–39), anti-human IgG2 (clone: HP6014), anti-human
IgG3 (clone: HP6050), anti-human IgG4 (clone: HP6023) (The
Binding Site, Birmingham, UK) diluted in 100ml of blocking
solution 1:64, 1:32, 1:50, 1:1,000, respectively, for 1 hour at 371C.
After washing, horseradish peroxidase-conjugated anti-mouse Ig
(Amersham Biosciences), diluted 1:1,500, was added for 1 hour
at 371C. Wells were washed and developed as described above.
For each serum, the mean OD reading obtained with GST was
subtracted from the mean reading obtained with GST-NC16A
or GST-316.
Competitive inhibition ELISA
Serum from patients or controls was diluted 1:100 in blocking
solution, added to the preincubation mixture with a molar excess of
the GST-316 fusion protein (100 mg/ml) or molar equivalent amount
of GST as control for 30 minutes at RT, then plated in duplicate wells
on ELISA plates coated with phages displaying BP180 epitopes. After
incubation and washing, the plates were incubated with peroxidase-
conjugated anti-human IgG and developed according to the phage-
ELISA protocol. The percentage of inhibition was determined by the
following formula: [1(OD450 GST-316/OD450 GST)] 100.
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Generation of anti-GST-316 polyclonal antibody
A rabbit polyclonal serum was generated against the GST-316 fusion
protein. Rabbit immunization was carried out by PRIMM, Milan,
Italy. The polyclonal antibody was specific for GST-316 as assessed
by ELISA and IB.
Affinity purification of antibodies from patient serum
Activated CH Sepharose 4B column (Amersham Biosciences) was
coupled with 2.6 mg of GST-316 in coupling buffer (0.1 M NaHCO3
(pH 8) and 0.5 M NaCl) and free amino groups were blocked with
0.1 M Tris-HCl (pH 8). After adsorption at RT and extensive washing
with phosphate-buffered saline, bound antibodies were eluted with
0.1 M glycine-HCl (pH 2.7) supplemented with BSA (10 mg/ml) and
immediately neutralized with 2 M Tris-HCl (pH 9.4). Affinity-purified
antibodies were checked for their reactivity by ELISA with the fusion
protein used for purification and, to assess specificity, with unrelated
GST-fusions. IgG autoantibodies specific for GST-316 were then
concentrated by using a 30,000 MWCO micro-concentrator tube
(Sartorius S.p.A., Florence, Italy). The reactivity against GST-316 by
ELISA of affinity-purified and concentrated serum was 10-fold higher
than that of the serum sample.
Statistical analyses
A cutoff value for each ELISA was established as a value 3 standard
deviations above the mean of OD450 obtained with 30 normal
healthy individual sera. The Fisher’s exact probability test was used
to compare the frequencies of PG sera and normal healthy individual
sera reactivity to BP180 epitopes. A P-valuep0.05 was considered
significant. All statistical analyses were performed using the SPSS
statistical package (SPSS, Chicago, IL).
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